Global Biopharmaceutical Company - Bristol Myers Squibb
Areas of focus
Bristol Myers Squibb is committed to discovering, developing and delivering transformational medicines in areas where we believe we have an opportunity to make a meaningful difference for patients.
2022 First Quarter Results >
Bristol Myers Squibb reports first quarter revenues of $11.6 Billion; GAAP EPS of $0.59 and non-GAAP EPS of $1.96 which include net impact of ($0.10) per share due to acquired IPRD charges partially offset by licensing income. Read more, including important cautionary statements about forward-looking information.
A subset of BMS.com, Life & Science Stories is our digital magazine where we share the work our global community of colleagues are doing around the world to help patients and advance scientific innovation.
Looking for Answers?
Quick links to helpful resources.